An announcement from bioAffinity Technologies, Inc. (BIAF) is now available.
At the bioAffinity Technologies, Inc. 2024 Annual Meeting, shareholders endorsed key proposals that shape the company’s future financial landscape. They voted in favor of the 2024 Incentive Compensation Plan, aimed at motivating employees through rewards, and approved a substantial increase in authorized common stock, from 25 million to 100 million shares. Additionally, the election of eight director nominees was confirmed, ensuring leadership stability until the next annual meeting. Shareholders also ratified the appointment of the Company’s independent public accounting firm and supported the issuance of shares upon warrant exercise, further solidifying the company’s strategic financial initiatives.
For a thorough assessment of BIAF stock, go to TipRanks’ Stock Analysis page.
